A novel screening platform combining matrix-entrapment peptide gradient arrays with cell-free protein synthesis to identify species-specific pollen tube attractant peptides. These peptides could serve as next-generation, environmentally friendly herbicides targeting sexual reproduction in unwanted plant species without persisting in ecosystems or requiring genetic modification of crops.
This research proposes a high-throughput discovery platform for identifying species-specific pollen attractant peptides that could be developed into a new class of biodegradable, targeted herbicides. Flowering plants rely on species-specific signaling peptides secreted by female tissues to guide pollen tube elongation during reproduction. By disrupting these natural chemical gradients, it may be possible to interfere with sexual reproduction in unwanted plant species while leaving the surrounding environment unaffected.
Unlike traditional herbicides that persist in soil and water and affect broad ranges of organisms, peptide-based herbicides offer a highly specific, biodegradable alternative compatible with non-genetically modified crops. This makes the technology particularly attractive for integrated pest management, organic agriculture, and conservation applications where environmental impact is a concern.
Core innovation:
Potential applications:
This is an early-stage research concept at TRL 1-2 (basic research and concept formulation). The screening platform itself has not yet been built or validated. Future work will involve constructing the matrix-entrapment array system, generating the cell-free peptide library, and conducting initial pollen tube chemotaxis assays to identify candidate attractant peptides. Significant additional research is required before any peptide candidates can be advanced toward field testing or product development.
Georgia Institute of Technology is a large, technology‑focused public research university in Atlanta with a strong applied research culture. Industry engages through the Georgia Tech Research Institute for contract R&D, a Midtown innovation district with co‑located corporate labs, and a statewide manufacturing extension to support scale‑up. A long‑standing partnership with a major academic medical center enables clinical translation, and a large co‑op program delivers a steady talent pipeline. Research is backed by competitive federal funding from NSF, NIH, DOE, DoD, and NASA. Technology commercialization is managed by the Georgia Tech Research Corporation, with dedicated licensing, corporate contracting, and startup support.